The cardiovascular and haematological effects of purified prothrombin activator derived from the venom of the Australian Common Brown Snake (Pseudonaja textilis) were studied in anaesthetised, mechanically ventilated dogs. Severe depression of systemic blood pressure and cardiac output and a rise in central venous pressure were observed. Thrombocytopenia, prolongation of both prothrombin time and activated partial thromboplastin time and a reduction in serum fibrinogen were also observed. All of these observed effects were prevented by the prior administration of heparin -a naturally occurring anticoagulant. We conclude that the prothrombin activator in Pseudonaja textilis venom may cause cardiovascular depression due to myocardial dysfunction secondary to disseminated intravascular coagulation.
this report, we endeavoured to characterise the cardiovascular and pro coagulant effects of prothrombin activator in the mechanically ventilated dog and to ascertain if the effects of the prothrombin activator are antagonised by heparin -a naturally occurring anticoagulant.
MATERIALS AND METHODS The prothrombin activator without neurotoxic activity was prepared as previously described, and stored at -20T, in a 50% glycerol-saline solution. 6 This preparation was shown to be stable for at least twelve months. Briefly, the prothrombin activator of the venom of Pseudonaja textilis was purified using a combination of con A-Sepharose and gel filtration of Sephacryl S-300, with a yield of 75%. This preparation of prothrombin activator was shown as a single band on polyacrylamide gel electrophoresis (PAGE) at pH 8.9 in a tris-glycine discontinuous buffer system. PAGE gels were stained with 0.2% coomassie blue in a mixture methanol:acetic acid:water (45: 10:45) and destained with the same mixture without stain.
Investigations were performed in anaesthetised, mechanically ventilated dogs. Anaesthesia was induced with intravenous thiopentone 8-15 mg/kg) and maintained with a mixture of halothane, oxygen and air via an endotracheal tube.
Anaesthesia and Intensive Care, Vol. 20, No. 1. February. 1992 Mechanical ventilation was provided with a volume-controlled ventilator (CF Palmer, London). Respiratory rate was fixed at 16/min while tidal volume was varied between 8-12 ml/kg to yield an end-tidal carbon dioxide of 4.5-5.5% using a CD-300 CO 2 analyser (Datex Instrumentarium, Helsinki, Finland). A catheter was positioned in the right atrium via a femoral or jugular vein, to enable measurement of central venous pressure. Arterial pressure was measured in the abdominal aorta by a catheter inserted via a femoral artery. Cardiac output was measured by a dye dilution technique using a COR-I OOA Cardiac Output Recorder (Waters Instruments, Minnesota, USA). A bolus of indocyamine was injected into the right atrium. Diluted samples were withdrawn from the contralateral femoral artery. A continuous electrocardiograph was displayed and recorded (Cardiovit CS-6 ECG Recorder, Schiller AG, Switzerland). Cardiovascular pressures were displayed by Electronics-for-Medicine (White Plains, New York, USA) monitors and recorded with a Curken paper recorder (Danbury, Connecticut, USA). Blood samples were SUbjected to routine laboratory tests of coagulation. Platelet counts were determined in blood films using an automated particle counter (Coulter S plus, Coulter Electronics Ltd, Hialeah, Florida, USA). Prothrombin time, activated partial thromboplastin time and serum fibrinogen levels were determined with a semi-automated machine (Cobas Fibro, Hoffmann-La Roche, Basle, Switzerland). Cross-linked fibrin degradation products were measured by Dimertest (Agen Biomedical, Acacia Ridge, Queensland, Australia). The study was approved by the hospital ethics committee. In a group offive dogs (Group A), glycerol buffer solution diluted with 0.9% saline in a dose of 10 Ilglkg was infused intravenously over a period of two minutes. After an interval of 5 to 10 minutes, prothrombin activator diluted with 0.9% saline was infused in a dose of 7 Ilg/kg over two minutes. In another group of four dogs (Group B), the same dose of prothrombin activator was administered after heparin sodium (Fisons, Thomleigh, NSW, Australia) had been infused in a dose of lOO U/kg. Cardiovascular measurements were recorded and blood samples withdrawn for analysis before the administration of prothrombin activator and heparin. Additional measurements were made and blood samples withdrawn at 5 to 10 and at 30 to 40 minutes after administration of prothrombin activator. The differences in cardiovascular indices at different times in each group of dogs were analysed for significance using repeated measures analysis of variance. The differences in cardiovascular indices between the two groups at 5 to 10 minutes after infusion of prothrombin activator were analysed using Student's t test. Analyses were performed with a computer statistical package (,Epistat', TL Gustafson, Richardson, Texas, USA).
RESULTS

PROTHROMBIN AcrIVATOR AWNE, GROUP A
Cardiovascular
No significant alteration was observed after infusion of glycerol buffer solution. In contrast, precipitous falls in blood pressure and cardiac output were observed 5 to 10 minutes after infusion of prothrombin activator. Compared with resting levels, the maximum decrement (mean±SD) in mean blood pressure was 60±9% (P < 0.005) with a '" Cardiovascular indices in five dogs before and after infusion of Pseudonaja textilis prothrombin activator (7 jJ.glkg) 
Pre-infusion
Post-infusion Mean values (SD) • P < 0.002 simultaneous decrement in cardiac output of 83±9% (P < 0.002) and an increase in peripheral vascular resistance. Central venous pressure increased significantly from 1.4±1.l to 7.4±2.1 mmHg (P < 0.002) while the heart rate increased 20.7±5.5% (not significant). Over the ensuing thirty minutes, blood pressure increased slowly to attain or exceed pre-prothrombin activator administration levels in four of the five dogs. Cardiac output and heart rate likewise were restored to near pre-prothrombin activator administration levels, but central venous pressure remained elevated. In one dog the blood pressure remained' low (23 mmHg) thirty minutes after infusion of prothrombin activator, after falling from 97 mmHg. This was associated with a persistently low cardiac output of 7.5 ml/kg/min (after falling from 152 ml!kg/min) and a high central venous pressure of 10 mmHg after rising from 2 mmHg. In all dogs, abnormalities on the electrocardiogram were observed: elevation of the ST segment and T -wave inversion were observed at the same time as the period of hypotension. Sinus rhythm was preserved in four of the five dogs (sinus tachycardia) but episodes of heart block and ventricular tachycardia were observed in the one dog which had persistent hypotension, low cardiac output and raised central venous pressure. The absolute changes observed in heart rate, blood pressure, central venous pressure, cardiac output, stroke volume and systemic vascular resistance before and after administration of prothrombin activator are presented in Table I .
Haemal%gica/
Severe thrombocytopenia was observed 5 to 10 minutes after intravenous infusion of prothrombin activator with the platelet count reduced to 5.0±4.0% (mean±SD) of the controls. At 30 to 40 minutes after prothrombin activator infusion, the platelet count had increased from that observed earlier but the levels remained low and were 31±16% of the pre-infusion levels. Laboratory tests of coagulation were grossly abnormal. Both prothrombin times and activated partial thromboplastin times were well in excess of the normal ranges. The tests performed at 5 to 10 minutes and at 30 to 40 minutes after infusion of the prothrombin activator were both in excess of 2 to 5 minutes. Serum fibrinogen levels were below the minimal level of detectability at both sampling times after administration of prothrombin activator. Cross-linked fibrin degradation products were not detectable at 5 to 10 and at 30 to 40 minutes after prothrombin activator infusion. The absolute values for the platelet count, prothrombin time, activated partial thromboplastin time, serum fibrinogen level and cross-linked fibrin degradation products for each dog before and after prothrombin activator infusion are presented in Table 2 .
HEPARIN-PROTHROMBIN ACTIVATOR, GROUP B
Cardiovascular
Marked alterations were not evident after the administration of heparin followed by the administration of prothrombin activator. Minor fluctuations only (not statistically significant) were noted in heart rate, blood pressure, central venous pressure and cardiac output. Differences ID calculated stroke volume and systemic vascular resistance likewise were not significantly changed. No electrocardiographic changes were observed.
Haematological
Heparin administration caused expected prolongation of activated partial thromboplastin times. After subsequent administration of prothrombin activator, the prothrombin times were not prolonged, platelet counts were not depressed and cross-linked fibrin degradation products were not elevated. Fibrinogen levels were slightly reduced after prothrombin activator from 194±68 mg/dl (mean±SD) to 137±36 mg/dl (difference not significant). The absolute values are presented in Table 3 .
Significant differences were observed in the cardiovascular indices between the two groups 5 to 10 minutes after infusion of the prothrombin activator. The group of dogs infused with prothrombin activator alone recorded lower blood pressure, cardiac output and stroke volume compared with the group pre-treated with heparin. The central venous pressure was significantly greater in the group not pre-treated with heparin. The comparative cardiovascular indices in the two groups are presented in Figure 1 .
DISCUSSION
Intravenous administration of purified
Pseudonaja textilis prothrombin activator resulted in marked cardiovascular depression and disturbance of coagulation. The cardiovascular effects were severe hypotension and low cardiac output accompanied by rising central venous pressure. These observations suggest myocardial failure. Signs of myocardial ischaemia were observed on the electrocardiograph. Simultaneously, uncontrolled activation of the coagulation system was suggested by depletion of platelets in the blood, prolongation of laboratory tests of coagulation and depletion of serum fibrinogen levels. It is likely that cardiovascular depression and coagulopathy are causally related. Thrombin, the catalytic product of prothrombin conversion, has been demonstrated to cause simultaneous hypotension and intravascular coagulation in rhesus monkeys and rabbits. I I Sublethal doses of thrombin induced hypotension with spontaneous recovery over 10 to 30 minutes. Lethal hypotension was attributed to right heart failure as a consequence of formation of thrombi within the pulmonary micro-circulation. Occasionally, macroscopic thrombi were observed in medium-sized pulmonary arteries and in one animal in a small coronary artery.
The anticoagulant activity of heparin is due to its potent antithrombin activity. It inhibits the activation ofthrombin by facilitating the action of antithrombin III on thrombin and other activated coagulation factors IX, X and XII. Pseudonaja textilis prothrombin activator is a powerful procoagulant which stimulates the formation of thrombin. Heparin has no direct effect on the activity of Pseudonaja textilis prothrombin activator in vitro. 12 This study revealed that pretreatment with heparin effectively prevents the procoagulant effect of Pseudonaja textilis prothrombin activator. Thrombocytopenia and prolongation of prothrombin time were not observed when heparin was administered before prothrombin activator. Presumably, heparin antagonises the procoagulant action of the prothrombin activator by facilitating the formation of an antithrombin III-thrombin complex.
Heparin has been suggested as a possible treatment of haemorrhage induced by Australian snake envenomation. 13 However, the efficacy of heparin in established coagulopathy induced by Pseudonaja venom has not been demonstrated. Moreover, the administration of an anticoagulant when clotting factors have already been depleted may pose a greater risk for spontaneous haemorrhage. Two human case reports of envenomation by Pseudonaja species in which heparin therapy was utilized did not claim any beneficial effects attributable to heparin therapy.14,IS Further experimentation of the use of heparin during established coagulopathy should be undertaken before routine clinical use. A theoretical role for heparin may be before the release of a pressure-immobilisation bandage in a victim effectively envenomated, assuming that the procoagulant had not reached the circulation. However, even in this scenario, administration of anti venom is the preferred treatment.
